Business Description
CSPC Pharmaceutical Group Ltd
ISIN : US12591J2078
Description
Financial Strength
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 18.52 | |||||
Equity-to-Asset | 0.72 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | 0.1 | |||||
Interest Coverage | 271.7 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 6.27 | |||||
Beneish M-Score | -2.59 | |||||
WACC vs ROIC |
Growth Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 12.1 | |||||
3-Year EBITDA Growth Rate | 17.7 | |||||
3-Year EPS without NRI Growth Rate | 17.9 | |||||
3-Year FCF Growth Rate | 43.7 | |||||
3-Year Book Growth Rate | 18.1 | |||||
Future 3-5Y EPS without NRI Growth Rate | 10.05 | |||||
Future 3-5Y Total Revenue Growth Rate | 7.6 |
Momentum Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 16.14 | |||||
9-Day RSI | 27.09 | |||||
14-Day RSI | 34.62 | |||||
6-1 Month Momentum % | 16.85 | |||||
12-1 Month Momentum % | -20.29 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.63 | |||||
Quick Ratio | 2.32 | |||||
Cash Ratio | 1.29 | |||||
Days Inventory | 110.77 | |||||
Days Sales Outstanding | 58.87 | |||||
Days Payable | 94.58 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 4.37 | |||||
Dividend Payout Ratio | 0.45 | |||||
3-Year Dividend Growth Rate | 28.7 | |||||
Forward Dividend Yield % | 4.9 | |||||
5-Year Yield-on-Cost % | 15.19 | |||||
3-Year Average Share Buyback Ratio | 0.1 | |||||
Shareholder Yield % | 4.08 |
Profitability Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 70.49 | |||||
Operating Margin % | 22.3 | |||||
Net Margin % | 18.66 | |||||
ROE % | 18.47 | |||||
ROA % | 13.36 | |||||
ROIC % | 25.75 | |||||
ROC (Joel Greenblatt) % | 65.35 | |||||
ROCE % | 21.44 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 10.5 | |||||
Forward PE Ratio | 10.72 | |||||
PE Ratio without NRI | 10.5 | |||||
Shiller PE Ratio | 18.25 | |||||
Price-to-Owner-Earnings | 8.96 | |||||
PEG Ratio | 0.53 | |||||
PS Ratio | 2.05 | |||||
PB Ratio | 1.96 | |||||
Price-to-Tangible-Book | 2.12 | |||||
Price-to-Operating-Cash-Flow | 8.36 | |||||
EV-to-EBIT | 6.98 | |||||
EV-to-Forward-EBIT | 6.74 | |||||
EV-to-EBITDA | 6.98 | |||||
EV-to-Forward-EBITDA | 6.22 | |||||
EV-to-Revenue | 1.64 | |||||
EV-to-Forward-Revenue | 1.52 | |||||
EV-to-FCF | 10.19 | |||||
Price-to-Projected-FCF | 0.95 | |||||
Price-to-DCF (Earnings Based) | 0.4 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.53 | |||||
Price-to-Graham-Number | 1.02 | |||||
Price-to-Net-Current-Asset-Value | 4.71 | |||||
Earnings Yield (Greenblatt) % | 14.33 | |||||
Forward Rate of Return (Yacktman) % | 24.77 |